The wearable injectors market size was valued at USD 8.07 billion in 2023. The market is projected to grow to USD 18.87 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.0% from 2024 to 2032.
Market Definition:
Wearable injectors, also called on-body injectors or patch pumps, are a notable advancement in medical device technology, especially for administering biological drugs and other complicated treatments. These devices aim to deliver larger doses of medication under the skin gradually, offering a substitute for common methods like IV drips and daily injections. Wearable injectors are commonly secured to the skin and set to deliver accurate doses of medication, enhancing patient convenience and commitment to treatment regimens.
๐๐๐ญ ๐๐ฑ๐๐ฅ๐ฎ๐ฌ๐ข๐ฏ๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ ๐๐ฌ ๐จ๐ ๐๐ก๐ข๐ฌ ๐๐๐ฉ๐จ๐ซ๐ญ:
https://www.polarismarketresearch.com/industry-analysis/wearable-injectors-market/request-for-sample
Growth Drivers and Opportunities:
- The increasing prevalence of chronic diseases worldwide is driving the growth of the wearable injectors market. Illnesses such as diabetes, autoimmune diseases, heart conditions, and cancer necessitate regular medication use, increasing the need for convenient ways to deliver drugs.
- Wearable injectors improve patient adherence and compliance by offering a comfortable and less invasive injection solution. The enhanced adherence results in improved disease control and health results for elderly individuals, consequently increasing the request for wearable injectors in the medical field.
Key Players:
With so many businesses involved, the market is projected to become more competitive as it continues to grow.
Here is the list of the leading companies operating in the market:
- Amgen Inc.
- Becton, Dickinson and Company
- CeQur SA
- Debiotech SA
- Elcam Medical
- Enable Injections
- Insulet Corporation
- Medtronic plc
- Roche Diagnostics International Ltd.
- Sorrel Medical
- Tandem Diabetes Care, Inc.
- Unilife Corporation
- United Therapeutics Corporation
- West Pharmaceutical Services, Inc.
- Ypsomed Holding AG
Report Segmentation
The research report categorizes the market into various segments and sub-segments. The primary segments covered in the study include type, technology, end use and indicaton. The splitting of the market into various groups enables businesses to understand market preferences and trends better. Also, stakeholders can develop products/services that align with the diverse needs of consumers in the industry.
Wearable Injectors Market, Type Outlook (Revenue – USD Billion, 2019-2032)
- Off-body
- On-body
Wearable Injectors Market, Technology Outlook (Revenue – USD Billion, 2019-2032)
- Rotary pump
- Spring-based
- Expanding battery
- Motor-driven
- Others
Wearable Injectors Market, End-use Outlook (Revenue – USD Billion, 2019-2032)
- Hospitals and Clinics
- Home Care
- Others
Wearable Injectors Market, Indication Outlook (Revenue – USD Billion, 2019-2032)
- Cardiovascular Diseases
- Oncology
- Immunodeficiency
- Infectious Diseases
- Autoimmune Diseases
- Others
Future Outlook
The future outlook for the wearable injectors market is highly promising, driven by evolving patient needs, advancements in biologic drug formulations, and increasing preferences for at-home healthcare solutions. Research efforts are focused on integrating smart connectivity features, developing more ergonomic and patient-friendly designs, and improving dosing precision through miniaturized sensors and electronic components. There is also growing interest in advanced materials and sustainable manufacturing practices to enhance the devicesโ comfort, reliability, and environmental impact. As regulations streamline and reimbursement policies become more favorable, ongoing research will likely result in innovative wearable injectors that are safer, easier to use, more affordable, and better suited to managing complex chronic conditions.
Recent Developments
June 2023:
Eitan Medical successfully completed the sale and transfer of its wearable injectors division to LTS, a leading pharmaceutical technology company known for its expertise in developing and manufacturing advanced drug delivery systems. This strategic transaction enhances LTS’s portfolio and strengthens its position in the wearable injectors market.
October 2023:
Enable Injections received FDA approval for the Empaveli Injector, a wearable device specifically designed for adults with paroxysmal nocturnal hemoglobinuria (PNH). This innovative device provides hands-free drug delivery of up to 25 mL, offering flexibility for use in both home and clinical settings, improving convenience and patient care.